HK1211944A1 - Novel insulin analog and use thereof - Google Patents
Novel insulin analog and use thereofInfo
- Publication number
- HK1211944A1 HK1211944A1 HK15112526.1A HK15112526A HK1211944A1 HK 1211944 A1 HK1211944 A1 HK 1211944A1 HK 15112526 A HK15112526 A HK 15112526A HK 1211944 A1 HK1211944 A1 HK 1211944A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- insulin analog
- novel insulin
- novel
- analog
- insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
- 239000004026 insulin derivative Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130020703 | 2013-02-26 | ||
| KR20130082511 | 2013-07-12 | ||
| KR20140006937 | 2014-01-20 | ||
| PCT/KR2014/001593 WO2014133324A1 (ko) | 2013-02-26 | 2014-02-26 | 신규한 인슐린 아날로그 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1211944A1 true HK1211944A1 (en) | 2016-06-03 |
Family
ID=51428522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15112526.1A HK1211944A1 (en) | 2013-02-26 | 2015-12-18 | Novel insulin analog and use thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20160008483A1 (ja) |
| EP (2) | EP3616727B1 (ja) |
| JP (3) | JP6552968B2 (ja) |
| KR (2) | KR20140106452A (ja) |
| CN (2) | CN104995206B (ja) |
| AU (2) | AU2014221531B2 (ja) |
| BR (1) | BR112015019985A2 (ja) |
| CA (1) | CA2901873C (ja) |
| CL (1) | CL2015002330A1 (ja) |
| DK (1) | DK2963056T3 (ja) |
| ES (2) | ES2868351T3 (ja) |
| HK (1) | HK1211944A1 (ja) |
| IL (1) | IL240717B (ja) |
| MX (1) | MX366400B (ja) |
| MY (1) | MY186990A (ja) |
| PE (2) | PE20151409A1 (ja) |
| PH (1) | PH12015501814A1 (ja) |
| PT (1) | PT2963056T (ja) |
| RU (1) | RU2676729C2 (ja) |
| SA (2) | SA515360933B1 (ja) |
| SG (2) | SG11201506095TA (ja) |
| TW (3) | TWI755579B (ja) |
| UA (1) | UA119533C2 (ja) |
| WO (1) | WO2014133324A1 (ja) |
| ZA (1) | ZA201507104B (ja) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| WO2014133324A1 (ko) * | 2013-02-26 | 2014-09-04 | 한미약품 주식회사 | 신규한 인슐린 아날로그 및 이의 용도 |
| MX369656B (es) | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| KR20150140177A (ko) | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
| JP2018508504A (ja) * | 2015-02-17 | 2018-03-29 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続型インスリンまたはインスリンアナログ結合体 |
| JP6987741B2 (ja) | 2015-07-24 | 2022-01-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 生理活性ポリペプチド結合体の製造方法 |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| EP3341405A4 (en) * | 2015-09-24 | 2019-05-01 | Hanmi Pharm. Co., Ltd. | PROCESS FOR INSULIN PRODUCTION |
| KR20180033105A (ko) * | 2016-09-23 | 2018-04-02 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
| WO2018105988A1 (ko) | 2016-12-05 | 2018-06-14 | 한미약품 주식회사 | 면역반응이 약화된 결합체 |
| CA3046337C (en) | 2016-12-09 | 2021-06-01 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| EP3578204A4 (en) * | 2017-02-03 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | BIOACTIVE SUBSTANCE CONJUGATE WITH ENHANCED DURABILITY AND ITS USE |
| WO2018147641A1 (ko) | 2017-02-07 | 2018-08-16 | 한미약품 주식회사 | 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법 |
| KR101941975B1 (ko) | 2017-03-17 | 2019-01-25 | 고려대학교 산학협력단 | Atpif1을 함유하는 당뇨 치료용 약학조성물 |
| EP3604328A4 (en) * | 2017-03-23 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE |
| WO2019066609A1 (ko) | 2017-09-29 | 2019-04-04 | 한미약품 주식회사 | 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법 |
| WO2019066603A1 (ko) | 2017-09-29 | 2019-04-04 | 한미약품 주식회사 | 효력이 향상된 지속성 단백질 결합체 |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| HRP20221418T1 (hr) | 2018-06-29 | 2023-01-06 | Akston Biosciences Corporation | Inzulin-fc fuzijski proteini ultra-dugog djelovanja i postupci uporabe |
| MX2021006972A (es) | 2018-12-11 | 2021-08-16 | Sanofi Sa | Conjugados de insulina. |
| CN113453703A (zh) | 2018-12-21 | 2021-09-28 | 韩美药品株式会社 | 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物 |
| JP2022514835A (ja) | 2018-12-21 | 2022-02-16 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン及びグルカゴンを含む薬学組成物 |
| AU2020321977C1 (en) * | 2019-07-31 | 2024-04-18 | Eli Lilly And Company | Relaxin analogs and methods of using the same |
| EP4282473A3 (en) * | 2019-12-19 | 2024-02-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| TW202204387A (zh) | 2020-03-31 | 2022-02-01 | 南韓商韓美藥品股份有限公司 | 新穎免疫刺激ｉｌ－２類似物 |
| KR20220167317A (ko) | 2020-04-10 | 2022-12-20 | 악스톤 바이오사이언시스 코퍼레이션 | Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법 |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CN113968911B (zh) * | 2020-07-24 | 2023-10-10 | 江苏晟斯生物制药有限公司 | 胰岛素-Fc融合蛋白及其应用 |
| WO2023004406A2 (en) | 2021-07-23 | 2023-01-26 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
| CN117769616A (zh) * | 2021-08-02 | 2024-03-26 | 丝芭博株式会社 | 合成皮革及其制造方法 |
| JPWO2023013640A1 (ja) * | 2021-08-02 | 2023-02-09 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| DE19735711C2 (de) * | 1997-08-18 | 2001-04-26 | Aventis Pharma Gmbh | Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| CN101743252A (zh) * | 2007-07-16 | 2010-06-16 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、peg化的胰岛素类似物 |
| US8481485B2 (en) * | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| US20120184488A1 (en) * | 2009-09-01 | 2012-07-19 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
| AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| KR101324828B1 (ko) * | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
| CA2806399A1 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| WO2014133324A1 (ko) * | 2013-02-26 | 2014-09-04 | 한미약품 주식회사 | 신규한 인슐린 아날로그 및 이의 용도 |
-
2014
- 2014-02-26 WO PCT/KR2014/001593 patent/WO2014133324A1/ko active Application Filing
- 2014-02-26 SG SG11201506095TA patent/SG11201506095TA/en unknown
- 2014-02-26 EP EP19197388.2A patent/EP3616727B1/en active Active
- 2014-02-26 SG SG10201907106VA patent/SG10201907106VA/en unknown
- 2014-02-26 TW TW108100374A patent/TWI755579B/zh active
- 2014-02-26 US US14/769,495 patent/US20160008483A1/en not_active Abandoned
- 2014-02-26 CN CN201480006998.4A patent/CN104995206B/zh active Active
- 2014-02-26 MX MX2015010471A patent/MX366400B/es active IP Right Grant
- 2014-02-26 TW TW106143717A patent/TWI708782B/zh active
- 2014-02-26 RU RU2015138536A patent/RU2676729C2/ru active
- 2014-02-26 KR KR1020140022909A patent/KR20140106452A/ko not_active IP Right Cessation
- 2014-02-26 CA CA2901873A patent/CA2901873C/en active Active
- 2014-02-26 MY MYPI2015001870A patent/MY186990A/en unknown
- 2014-02-26 EP EP14757629.2A patent/EP2963056B1/en active Active
- 2014-02-26 UA UAA201507940A patent/UA119533C2/uk unknown
- 2014-02-26 TW TW103106674A patent/TWI621626B/zh active
- 2014-02-26 PE PE2015001747A patent/PE20151409A1/es active IP Right Grant
- 2014-02-26 PT PT147576292T patent/PT2963056T/pt unknown
- 2014-02-26 JP JP2015559199A patent/JP6552968B2/ja active Active
- 2014-02-26 ES ES19197388T patent/ES2868351T3/es active Active
- 2014-02-26 ES ES14757629T patent/ES2770776T3/es active Active
- 2014-02-26 CN CN202210291419.1A patent/CN114989289A/zh active Pending
- 2014-02-26 BR BR112015019985A patent/BR112015019985A2/pt active Search and Examination
- 2014-02-26 DK DK14757629.2T patent/DK2963056T3/da active
- 2014-02-26 PE PE2019001804A patent/PE20191481A1/es unknown
- 2014-02-26 AU AU2014221531A patent/AU2014221531B2/en active Active
-
2015
- 2015-08-18 PH PH12015501814A patent/PH12015501814A1/en unknown
- 2015-08-19 CL CL2015002330A patent/CL2015002330A1/es unknown
- 2015-08-20 IL IL240717A patent/IL240717B/en active IP Right Grant
- 2015-08-23 SA SA515360933A patent/SA515360933B1/ar unknown
- 2015-08-23 SA SA518400491A patent/SA518400491B1/ar unknown
- 2015-09-25 ZA ZA2015/07104A patent/ZA201507104B/en unknown
- 2015-12-18 HK HK15112526.1A patent/HK1211944A1/xx unknown
-
2018
- 2018-05-18 US US15/983,923 patent/US20180256731A1/en not_active Abandoned
- 2018-11-22 AU AU2018267648A patent/AU2018267648B2/en active Active
-
2019
- 2019-07-03 JP JP2019124525A patent/JP2019187440A/ja active Pending
-
2021
- 2021-08-19 JP JP2021133932A patent/JP2021193089A/ja active Pending
- 2021-08-19 KR KR1020210109688A patent/KR102413691B1/ko active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1211944A1 (en) | Novel insulin analog and use thereof | |
| HK1223246A1 (zh) | 疼痛藥物組合及其用途 | |
| HK1223975A1 (zh) | 含納米氣泡的組合物及其用途 | |
| GB202005994D0 (en) | Patient interface and aspects thereof | |
| HK1203493A1 (en) | Substituted azabicycles and use thereof | |
| GB201317286D0 (en) | Composition and Use | |
| ZA201605626B (en) | Long-acting insulin and use thereof | |
| GB201305277D0 (en) | Novel combination and use | |
| EP3006066A4 (en) | INSTRUMENT FOR INJECTION, AND SYRINGE BULB | |
| HK1224234A1 (zh) | 注射器以及注射器組件 | |
| IL244214A0 (en) | Thienopiperidine derivative and its use | |
| IL243433B (en) | Titanium bibory layers and their production | |
| HK1203198A1 (en) | Substituted phenylimidazopyrazoles and use thereof | |
| IL244751A0 (en) | Cyclic thianouracil-carboxamides and their use | |
| SG11201510150VA (en) | Immunotherapy composition and use thereof | |
| PT2943239T (pt) | Elemento de fixação e seringa | |
| GB201307989D0 (en) | Novel combinations and use | |
| GB201301979D0 (en) | New composition and use thereof | |
| EP3006067A4 (en) | SYRINGE AND PRE-FILLED SYRINGE | |
| HK1207154A1 (en) | C1q-adiponectin complex and use thereof c1q- | |
| GB201307049D0 (en) | Catalysts and use thereof | |
| GB201322467D0 (en) | Composition and use | |
| GB201309328D0 (en) | Product and use thereof | |
| GB201313605D0 (en) | Novel compounds and their use |